Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Invasive Breast Cancer: early-phase trial registry
9 of 20 indexed Invasive Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #848 of 28,707 conditions by registered trial count.
20 US clinical trials · 9 currently recruiting · #848 of 28,707 conditions by registered trial count
Invasive Breast Cancer: 20 US clinical trials tracked, 9 recruiting.
Invasive Breast Cancer is the subject of 20 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition invasive-breast-cancer
OPEN 9 | RECR 45% | LATE 0 | EARLY 13 | RANK #848 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Germ Cell Tumor (45% recruiting · 20 trials)
Invasive Breast Cancer lists 9 open slots (45% of 20 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Invasive Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Invasive Breast Cancer is recruiting above its size-band peers.
9 of 20 indexed trials (45%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Invasive Breast Cancer research.
Memorial Sloan Kettering Cancer Center accounts for 3 of 20 trials (15%). 18 distinct sponsors appear on at least one study for this condition label.
-
Most Invasive Breast Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 86 among the 20 trials that report a genuine target (sentinel values excluded). 13 of those (65%) plan for fewer than 100 participants.
-
Invasive Breast Cancer research is mostly interventional.
16 interventional and 4 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
20 total, page 1 of 1
Sacituzumab Govitecan In TNBC
Massachusetts General Hospital
NCT04230109
Prospective Breast Cancer Biospecimen Collection
Thomas Jefferson University
NCT04074720
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Jonsson Comprehensive Cancer Center
NCT04553770
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Atossa Therapeutics
NCT05607004
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
NCT06268665
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Brigham and Women's Hospital
NCT04368702
TRUDI: TDXD+Durva in HER2+/Low IBC
Filipa Lynce, MD
NCT05795101
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT05412225
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
Wake Forest University Health Sciences
NCT04677816
Genetic Testing for All Breast Cancer Patients (GET FACTS)
Dana-Farber Cancer Institute
NCT04245176
Olaparib In Metastatic Breast Cancer
Beth Israel Deaconess Medical Center
NCT03344965
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
Ana C Garrido-Castro, MD
NCT04448886
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04648904
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
Medical College of Wisconsin
NCT04243616
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
NCT03387553
Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions
Case Comprehensive Cancer Center
NCT02802553
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
Memorial Sloan Kettering Cancer Center
NCT00581750
Breast Cancer Genome Guided Therapy Study (BEAUTY)
Mayo Clinic
NCT02022202
Digital Breast Tomosynthesis Versus Contrast Enhanced Magnetic Resonance Imaging (MRI) for Breast Cancer Staging
Dartmouth-Hitchcock Medical Center
NCT01060085
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Invasive Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Invasive Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Invasive Breast Cancer page
20 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Invasive Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Invasive Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Invasive Breast Cancer condition card totals 20 registered trials; most-linked intervention Sacituzumab Govitecan; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.